AU6865100A - Osteogenesis promoting agents - Google Patents

Osteogenesis promoting agents

Info

Publication number
AU6865100A
AU6865100A AU68651/00A AU6865100A AU6865100A AU 6865100 A AU6865100 A AU 6865100A AU 68651/00 A AU68651/00 A AU 68651/00A AU 6865100 A AU6865100 A AU 6865100A AU 6865100 A AU6865100 A AU 6865100A
Authority
AU
Australia
Prior art keywords
promoting agents
osteogenesis promoting
osteogenesis
agents
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68651/00A
Inventor
Kazuyuki Itoh
Hideki Yoshikawa
Kiyoko Yoshioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Welfide Corp filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU6865100A publication Critical patent/AU6865100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
AU68651/00A 1999-09-02 2000-08-30 Osteogenesis promoting agents Abandoned AU6865100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11/249383 1999-09-02
JP24938399 1999-09-02
PCT/JP2000/005871 WO2001017562A1 (en) 1999-09-02 2000-08-30 Osteogenesis promoting agents

Publications (1)

Publication Number Publication Date
AU6865100A true AU6865100A (en) 2001-04-10

Family

ID=17192198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68651/00A Abandoned AU6865100A (en) 1999-09-02 2000-08-30 Osteogenesis promoting agents

Country Status (2)

Country Link
AU (1) AU6865100A (en)
WO (1) WO2001017562A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
JP5042419B2 (en) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 Bone formation promoter and composition for promoting bone formation
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006088088A1 (en) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Pain remedy containing rock inhibitor
CN101253152A (en) 2005-09-02 2008-08-27 安斯泰来制药株式会社 Amide derivatives as ROCK inhibitors
WO2010026701A1 (en) * 2008-09-03 2010-03-11 国立大学法人東北大学 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient
WO2010026760A1 (en) * 2008-09-03 2010-03-11 富士フイルム株式会社 Compositions wherein bioactive components are stably sealed
ES2938049T3 (en) 2009-10-16 2023-04-04 Scripps Research Inst Induction of stem cells
CN114164167A (en) 2010-12-22 2022-03-11 菲特治疗公司 Cell culture platform for single cell sorting and enhanced IPSC reprogramming
JP2015047076A (en) * 2013-08-29 2015-03-16 独立行政法人産業技術総合研究所 Cell culture substrate, method for differentiation-inducing of osteoblasts using the same and method for producing osteoblasts
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
CN106572997A (en) 2014-05-30 2017-04-19 辉瑞公司 Carbonitrile derivatives as selective androgen receptor modulators
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CN117737124A (en) 2015-10-16 2024-03-22 菲特治疗公司 Platform for inducing and maintaining ground state pluripotency
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
CA3141455A1 (en) 2019-05-20 2020-11-26 Ajinomoto Co., Inc. Expansion culture method for cartilage or bone precursor cells
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US6008230A (en) * 1995-10-16 1999-12-28 Fujisawa Pharmaceutical Co., Ltd. Quinoline compounds as H+ -ATPases
BR9611210A (en) * 1995-10-23 1999-12-28 Zymogenetics Inc Compositions and processes for treating deficient bone conditions
SI0956865T2 (en) * 1996-08-12 2011-04-29 Mitsubishi Pharma Corp MEDICINES COMPRISING Rho KINASE INHIBITOR
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
AUPP003197A0 (en) * 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds

Also Published As

Publication number Publication date
WO2001017562A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
AU5325400A (en) Multi-connection via
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU6865100A (en) Osteogenesis promoting agents
AU3515300A (en) Efficient microprocessor architecture
AU5250400A (en) Osteogenesis promoters
AU2829600A (en) Osteogenesis promoters
AU5967600A (en) Candystraw
AU4115400A (en) Short-circuiter
AU6335000A (en) Depthimeter
AU7514700A (en) Cyanopiperidines
AU6440900A (en) Homogentisate-dioxygenase
AU2023701A (en) Sketcher
AU2804600A (en) Arylaminoalkylamides
AU2699800A (en) Organoceramics
AU6098300A (en) Follistatin-3
AU4916900A (en) Benzofuranylsulfonates
AU4561600A (en) Benzofuranylaminoalcohols
AU1901801A (en) Glucofuranoses
AU4435300A (en) Hula-hoop
AU2582200A (en) Windturbine
AU1915601A (en) Periotome
AU7303400A (en) Osseo-distractor
AU7513400A (en) Hydantoin-racemase
AU3065500A (en) Anti-inflammatory agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase